AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.

Autor: Sakemura RL; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Hefazi M; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Cox MJ; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Siegler EL; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Sinha S; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Hansen MJ; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Stewart CM; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota.; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota., Feigin JM; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Manriquez Roman C; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota.; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota., Schick KJ; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Can I; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Tapper EE; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Horvei P; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Adada MM; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Bezerra ED; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Kankeu Fonkoua LA; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Ruff MW; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Department of Neurology, Mayo Clinic, Rochester, Minnesota., Forsman CL; T Cell Engineering, Mayo Clinic, Rochester, Minnesota., Nevala WK; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Boysen JC; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Tschumper RC; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Grand CL; Sumitomo Dainippon Pharma Oncology, Inc. Lehi, Utah., Kuchimanchi KR; Sumitomo Dainippon Pharma Oncology, Inc. Lehi, Utah., Mouritsen L; Sumitomo Dainippon Pharma Oncology, Inc. Lehi, Utah., Foulks JM; Sumitomo Dainippon Pharma Oncology, Inc. Lehi, Utah., Warner SL; Sumitomo Dainippon Pharma Oncology, Inc. Lehi, Utah., Call TG; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Parikh SA; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Ding W; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Kay NE; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Kenderian SS; T Cell Engineering, Mayo Clinic, Rochester, Minnesota.; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Department of Immunology, Mayo Clinic, Rochester, Minnesota.; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2023 Sep 01; Vol. 11 (9), pp. 1222-1236.

Should Measurement of Maximum Urinary Flow Rate and Residual Urine Volume be a Part of a "Minimal Care" Assessment Programme in Female Incontinence?

Autor: Sander, P.¹, Mouritsen, L.², Thorup Andersen, J.¹, Fischer-Rasmussen, W.²

Publikováno v: Scandinavian Journal of Urology & Nephrology. Apr2002, Vol. 36 Issue 2, p124-127. 4p. 3 Charts.

Results after vaginal repair of recurrent prolapse with and without xenograft reinforcement - a randomized study

Autor: Mouritsen, L, Glavind, Karin, Bek, Karl Møller, Toozs-Hobson, P

Publikováno v: Mouritsen, L, Glavind, K, Bek, K M & Toozs-Hobson, P 2009, ' Results after vaginal repair of recurrent prolapse with and without xenograft reinforcement-a randomized study ', Como, Italy, 16/06/2009-20/06/2009, .
Mouritsen, L, Glavind, K, Bek, K M & Toozs-Hobson, P 2009, ' Results after vaginal repair of recurrent prolapse with and without xenograft reinforcement-a randomized study ', Somo, Italy, 16/06/2009-20/06/2009, .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8cf01ee508477692ebd5430fb21459b4
https://pure.au.dk/portal/da/publications/results-after-vaginal-repair-of-recurrent-prolapse-with-and-without-xenograft-reinforcement--a-randomized-study(3125f400-1fa5-11df-b95d-000ea68e967b).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.

Autor: Taverna JA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas., Hung CN; Department of Life Science, Tunghai University, Taichung, Taiwan.; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., DeArmond DT; Department of Cardiothoracic Surgery, University of Texas Health Science Center, San Antonio, Texas., Chen M; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Lin CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Osmulski PA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Gaczynska ME; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Wang CM; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Lucio ND; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chou CW; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chen CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Nazarullah A; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Lampkin SR; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Qiu L; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Bearss DJ; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Warner S; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Whatcott CJ; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Mouritsen L; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Wade M; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Weitman S; Institute for Drug Development, University of Texas Health Science Center, San Antonio, Texas., Mesa RA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas., Kirma NB; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chao WT; Department of Life Science, Tunghai University, Taichung, Taiwan. huangt3@uthscsa.edu wtchao@thu.edu.tw., Huang TH; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas. huangt3@uthscsa.edu wtchao@thu.edu.tw.

Publikováno v: Cancer research [Cancer Res] 2020 Apr 01; Vol. 80 (7), pp. 1551-1563. Date of Electronic Publication: 2020 Jan 28.